EPSTI1

Across TCGA pan-cancer cohorts, EPSTI1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EPSTI1 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EPSTI1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPSTI1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and COAD are the cancer types where EPSTI1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	1.000	0.372	.022	25	view →
LUAD	DFS	Median	III,IV	0.967	0.551	.003	16	view →
COAD	DFS	Quartile	III,IV	0.831	1.000	.039	12	view →
GBM	DFS	Median	All	0.445	0.306	.026	5	view →
LSCC	DFS	Median	II,III,IV	1.000	0.502	.038	3	view →
CCRCC	DFS	Quartile	All	0.849	0.630	.026	1	view →
PDAC	DFS	Quartile	All	0.626	0.796	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EPSTI1–HNSC (DFS)

Open the HNSC breakdown →